Acurx Pharmaceuticals is a late-stage biopharmaceutical company developing a novel class of small molecule antibiotics targeting difficult-to-treat Gram-positive bacterial infections by inhibiting DNA polymerase IIIC, an enzyme essential for bacterial DNA replication. The company's lead product, ibezapolstat, is a first-in-class DNA polymerase IIIC inhibitor in Phase 3 clinical trials for Clostridioides difficile infection, with Phase 2 data demonstrating efficacy comparable to vancomycin while preserving beneficial gut bacteria; the pipeline includes additional candidates targeting resistant pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Acurx generates revenue through milestone-based royalty arrangements with its predecessor sponsor and pursues partnerships with integrated pharmaceutical companies for late-stage development and commercialization, while monetizing its products at premium pricing reflecting the substantial unmet medical need in treating antibiotic-resistant infections.